Search

Rising life expectancy and increasing pressure on healthcare and social systems are driving a new market focused on prevention, independence, and quality of life for older adults.

BCN HEALTH will participate in the Jornadas AES, which will take place in Seville from June 17 to 19.

The new unit will be headed by Pablo Estebaranz Ruiz, an electronics engineer and European Patent Attorney (EPA)with over 18 years of experience.

The company has been recognised for the European project SustaiNext and its DYANA technology, a pioneering intelligent biorefinery model based on the circular economy.

Autónoma University of Madrid and Complutense University of Madrid founded the science incubator in 2001.

The biomedical Company MSD, a leader in research, has reached a new milestone in its commitment to science and innovation in Spain.

Asabys launches a fund of up to €120M to transform scientific discoveries into innovative healthcare companies, reinforcing its commitment to technology transfer and the creation of deep tech

Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract submission cut-off.

Partnership during the last 8 years leverages VIVEbiotech’s decade of experience manufacturing GMP ex- and in- vivo lentiviral vectors for the advanced therapies sector.

Transfection-free stable producer cell line (SCL) offers easy scalability, reduction of cost of goods (COGs), improve vector quality, and low batch variability.

We welcome the Biotech Act I, but believe its ambition and level of specificity must be strengthened to ensure a real impact on funding, industrial scale-up, and biotechnology innovation in Europe; a

Rubén Pérez-Mañanes is an orthopaedic oncology surgeon at the HGUGM (Gregorio Marañón University General Hospital), deputy director of the Gregorio Marañón Health Research Institute and an ANECA

Meet StablePharma, our new member. We spoke with Lorena Carmona Rodríguez, Lab Manager/Senior Scientist.

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12

These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the FiCAT gene-writing platform.

Meet AllBiotech, our new member. We spoke with Pablo Goñi, CEO.

The company presented its new Branded Ingredient at Vitafoods Europe, the nutraceutical industry trade show, which took place this week in Barcelona

The Dutch company is bolstering Málaga’s advanced technology ecosystem with a total investment of €32 million.

Innovation in healthcare does not arise solely from good ideas, but from an institutional architecture capable of attracting talent, coordinating capabilities and accelerating translation.

The agreement combines the preclinical models developed by the Institute of Biomedical Research of Barcelona (IIBB-CSIC) with the computational design platform of the company Chemotargets, based at